Quality of life and direct cost regarding blepharospasm and hemifacial spasm patients treated with botulinum toxin A;Qualidade de vida e custos diretos em pacientes com blefaroespasmo essencial e espasmo hemifacial, tratados com toxina botulínica-A

Arquivos Brasileiros de Oftalmologia

Volumn 67, Issue 1, 2004, Pages 43-49

  Osaki, Midori Hentona ^a   Belfort Jr , Rubens ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Blepharospasm therapy drug therapy; Botulinum toxin type A economics; Botulinum toxin type A therapeutic use; Drug costs; Health care costs; Hemifacial spasm drug therapy; Life of quality

Indexed keywords

EID: 33746350559     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/s0004-27492004000100008     Document Type: Article

References (28)

1. Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in blefarospasm and hemifacial spasm. J Neurol 2001;248(supl1):21-24
2. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985;103:347-350
3. Ainsworth JR, Kraft SP. Long-term changes in duration of relief with botulinum toxin treatment of essencial blepharospasm and hemifacial spasm. Ophthalmology 1995;102:2036-2040
4. Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993;4:834-836
5. Barbosa ER, Haddad MS, Silva HCA, Carvalho MJ, Bittar MS. Espasmo hemifacial: tratamento com toxina botulínica. Arq Bras Neurocir 1994;13:119-122
6. Andrade LA, Borges V, Ferraz HB, Azevedo-Silva SM. Experiência com aplicação de toxina botulínica A em 115 pacientes. Arq Neuropsiquiatr 1997; 55(3B):553-557
7. Borodic GE. Hemifacial spasm: evaluation and management, with emphasis on botulinum toxin therapy. In: Jankovic J, Hallett M, editors. Neurological disease and therapy. Therapy with botulinum toxin. New York: Marcel Dekker: 1994. p.331-351
8. Cunha MC, Aguirre OP, Dias CRS. Tratamento do espasmo facial unilateral com toxina botulínica tipo A. Arq Bras Oftalmol 1998;61:54-60.
9. Dodel RC, Kirchner A, Koehne-Volland R, Künig G, Ceballos-Baumann A, Naumann M, et al. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics 1997;12:695-706.
10. Bell MS, Vermeulen, LC Sperling KB. Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin. Pharmacotherapy 2000;20:1079-1091
11. Huang, W, Jill A, Rogachefsky, A. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000;43:249-259
12. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973;12:924-927
13. Müller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, et al. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 2002;249:842-846
14. Ware JE, Snow KK, Kosinski M. Scoring the SF-36. SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
15. Ciconelli RM. Tradução para o português e validação do questionário de avaliação de qualidade de vida "Medical outcomes study 36 -item short-form healty survey (SF-36)" [tese]. S.Paulo: Universidade Federal de S. Paulo; 1997.
16. Fahn S. The assessment of the primary dystonias. In: Munsat: TL, editor. The quantification of neurologic deficit. Boston: Butterworth;1989. p.242-245
17. Lindeboom R, De Haan R, Aramidesh M, Speelman JD. The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm. Mov Disord 1995;10:444-449
18. Secretaria de Estado da Saúde de São Paulo. Ata de registro de preços. [online]. (citado 2003 Jun 27]. Disponível em URL http:/www.farma.saude.sp.gov.br/ata/SsaudeTMedic.asp
19. Brasil. Ministério da Saúde. DATASUS. Gasto médio (SUS) por atendimento ambulatorial [online]. [citado 2003 set 27]. Disponível em URL: http:// tabnet.datasus.gov.br/cgi/idb2001/e10.pdf
20. Tucha O, Naumann M, Alders GL, Lange KW. Quality of life in patients with blepharospasm. Acta Neurol Scand 2001;103:49-52.
21. Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J. Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry 2001;71:193-195
22. Gudex CM, Hawthorne MR, Butler AG, Duffey P. Effect of dystonia and botulinum toxin treatment on health-related quality of life. Mov Disord 1998;13:941-949
23. Brefel-Courbon C, Simonetta-Moreau M, Moré C, Rascol O, Clanet M, Montastruc JL, et al. A pharmacoeconomia evaluation of botulinum toxin in the treatment of spasmodic torticollis. Clin Neuropharmacol 2000;23:203-207
24. Gudex CM, Hawthorne MR, Butler AG, Duffey PO. Measuring patient benefit from botulinum toxin in the treatment of dystonia. Feasibility of cost-utility analysis. Pharmacoeconomics. 1997;12:675-684
25. Schnider P, Birner P, Moraru E, Auff E. Long-term treatment with botulinum toxin: dosage, treatment schedules and costs. Wien Klin Wochenschr 1999;111:59-65.
26. Wenzel T, Schnider P, Gringl H, Birner P, Nepp J, Auff E. Psychiatric disorders in patient with blepharospasm - a reactive pattern? J Psych Res 2000;48:589-591
27. Scheidt CE, Schuller B, Rayki O, Kommerell G, Deuschl G. Relative absence of psychopathology in bening essential blepharospasm and hemifacial spasm. Neurology 1996;47:43-45
28. World Health Organization. Comparison on selected indicator WHO Region. Brazil. (Comparaed with other countries in WHO Region of the Americas) Indicator: Per capita government expenditure on health at average exchange rate (US$), 2000. [online]. [citado 2003 set 27]. Genebra, WHO. Available from URL: http://www3.who.int/whosis/country/compare.cfm?language= en&country= bra&indicator=strPcGovEOHinUSD2000